Skip to content

Effectiveness and safety of a kind of Chinese herbal medicine compound combination in the treatment of portal hypertensive gastropathy in cirrhosis:protocol for a clinical study

Effectiveness and safety of a kind of Chinese herbal medicine compound combination in the treatment of portal hypertensive gastropathy in cirrhosis:protocol for a clinical study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041166
Enrollment
Unknown
Registered
2020-12-20
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

portal hypertensive gastropathy in cirrhosis

Interventions

Sponsors

Kailuan General Hospital, Tangshan, Hebei
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Comply with the diagnostic standards of Western medicine PHG in cirrhosis. (2) The age is between 18-75 years old. (3) Patients with no or small ascites, no upper gastrointestinal bleeding and hepatic encephalopathy. (4) In the near future, people who take vasoactive drugs such as cardiotonic, nifedipine, nitrates and diuretics need to stop drugs for more than one week, and then observe the indexes after stabilization. (5) Those who have voluntarily signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with severe diseases such as malignant hypertension, severe arrhythmia, acute myocardial infarction, cerebrovascular accident, etc. (2) Patients with acute infection, trauma, surgery, diabetic ketoacidosis, and hyperosmolar coma recently. (3) Patients with severe primary diseases such as brain, liver, kidney and hematopoietic system, mental illness and cognitive dysfunction. (4) Patients with tumor and other organ failure.

Design outcomes

Primary

MeasureTime frame
Gastroscopy;liver function;C-reactionprotein;Somatostatin;Helicobacter pylori;anti-parietal cell antibody;

Countries

China

Contacts

Public ContactDu Liming

Kailuan General Hospital, Tangshan, Hebei

camma6@163.com+86 315-3021114

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026